Agreements reached under this partnership
Business allianceApproximately 120 patients are expected to be enrolled. The primary endpoint is the change from baseline in the total PANSS score on Day 35.
We will receive a $22.5 million milestone payment (approximately ¥3,574 million), which is expected to be recognized in full as revenue for the first quarter of the fiscal year ending December 2026. The impact on our consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Neurocrine Biosciences Inc.（ニューロクライン社） |
| Type of alliance | Business alliance |
| Numerical targets under the alliance | Approximately 120 patients are expected to be enrolled. The primary endpoint is the change from baseline in the total PANSS score on Day 35. |
| Impact on Business Performance | We will receive a $22.5 million milestone payment (approximately ¥3,574 million), which is expected to be recognized in full as revenue for the first quarter of the fiscal year ending December 2026. The impact on our consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A contractual milestone payment will be triggered by Neurocrine Biosciences Inc.'s initiation of the Phase 2 trial of NBI-1117570 and dosing of the first patient.